M
Michael S. Gordon
Researcher at Pinnacle Financial Partners
Publications - 172
Citations - 13887
Michael S. Gordon is an academic researcher from Pinnacle Financial Partners. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 43, co-authored 153 publications receiving 12207 citations. Previous affiliations of Michael S. Gordon include GlaxoSmithKline & Indiana University – Purdue University Indianapolis.
Papers
More filters
Journal ArticleDOI
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Antonio Jimeno,Kathleen N. Moore,Kathleen N. Moore,Michael S. Gordon,Rashmi Chugh,Jennifer R. Diamond,Raid Aljumaily,Raid Aljumaily,David S. Mendelson,Ann M. Kapoun,Lu Xu,Robert Joseph Stagg,David Smith +12 more
TL;DR: Navicixizumab can be safely administered with manageable toxicities and these data showed preliminary signs of antitumor activity in multiple tumor types, but was most promising in ovarian cancer, which justifies its continued development in combination Phase 1b clinical trials.
Journal ArticleDOI
Myeloid Progenitor Cell Proliferation and Mobilization Effects of BB10010, a Genetically Engineered Variant of Human Macrophage Inflammatory Protein-1α, in a Phase I Clinical Trial in Patients with Relapsed/Refractory Breast Cancer
Hal E. Broxmeyer,Attilio Orazi,Nancy Hague,George W. Sledge,Henrik Rasmussen,Michael S. Gordon +5 more
TL;DR: The results demonstrate in humans the suppressive and mobilizing effects of MIP-1alpha and BB10010 previously noted in vivo in mice.
Journal Article
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.
Attilio Orazi,Ryan J. Cooper,J. Tong,Michael S. Gordon,Battiato L,George W. Sledge,Kaye Ja,Kahsai M,Ronald Hoffman +8 more
TL;DR: The results indicate that the administration of rhIL-11 to patients with normal hematopoiesis stimulates MK endoreduplication, PCNA expression, and, at high doses, increases MK and CFU-MK progenitor cell numbers.
Journal ArticleDOI
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)
Ryan B. Corcoran,T. Andre,Takayuki Yoshino,Johanna C. Bendell,Chloe E. Atreya,J.H.M. Schellens,Michel Ducreux,Autumn J. McRee,Salvatore Siena,Gary Middleton,Michael S. Gordon,Yves Humblet,K. Muro,Elena Elez,Rona Yaeger,Roger Sidhu,Matthew Squires,Savina Jaeger,Fatima Rangwala,E. Van Cutsem +19 more
Journal ArticleDOI
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
Shailender Bhatia,Brendan D. Curti,Marc S. Ernstoff,Michael S. Gordon,Elisabeth I. Heath,Wilson H. Miller,Igor Puzanov,David I. Quinn,Thomas W. Flaig,Peter J. Vanveldhuizen,Kelly Byrnes-Blake,Jeremy A Freeman,Rachel Bittner,Naomi Hunder,Sonia Souza,John A. Thompson +15 more
TL;DR: IL-21 plus sorafenib has antitumor activity and acceptable safety in previously treated mR CC patients, and may represent a suitable immunotherapy in further exploration of combination strategies in mRCC.